Back
News
1 min read

Press Release: Start-up XENOTHERA closes a new capital increase above 2 million euros

  • Bertrand Fabien
  • Author Bertrand Fabien
  • Published 10 juin 2016

Related Posts

XENOTHERA Welcomes the National Academy of Medicine’s Call for a National Xenotransplantation Plan and Reaffirms Its Commitment to This Breakthrough Medical Innovation

May, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…

Read More

XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials.

December, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….

Read More

XENOTHERA successfully secures €4 Million non-dilutive financing from the France 2030 Public Investment Plan for its LIS22 treatment for peripheral T-Cell lymphoma.

November, 2024. The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis.

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr
Linkedin-in